Proteasome Inhibitors and Bone Disease

Seminars in Hematology

Volumn 49, Issue 3, 2012, Pages 243-248

  Qiang, Ya Wei ^a   Heuck, Christoph J ^a   Shaughnessy, John D ^a,b   Barlogie, Bart ^a   Epstein, Joshua ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Signal Genetics LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BETA CATENIN; BORTEZOMIB; MESSENGER RNA; MG 262; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEASOME INHIBITOR; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; BONE DEVELOPMENT; BONE DISEASE; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; METABOLIC REGULATION; MULTIPLE MYELOMA; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST ACTIVITY; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DISEASES; HUMANS; MULTIPLE MYELOMA; OSTEOCLASTS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS;

EID: 84862653565     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2012.04.011     Document Type: Article

References (69)

1. Roodman G.D. Pathogenesis of myeloma bone disease. Blood Cells Mol Dis 2004, 32:290-292.
2. Giuliani N., Bataille R., Mancini C., Lazzaretti M., Barille S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001, 98:3527-3533.
3. Pearse R.N., Sordillo E.M., Yaccoby S., et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 2001, 98:11581-11586.
4. Bataille R., Chappard D., Marcelli C., et al. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol 1989, 7:1909-1914.
5. Richardson P.G., Mitsiades C., Hideshima T., Anderson K.C. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 2006, 57:33-47.
6. Terpos E., Sezer O., Croucher P., Dimopoulos M.A. Myeloma bone disease and proteasome inhibition therapies. Blood 2007, 110:1098-1104.
7. Zangari M., Esseltine D., Lee C.K., et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 2005, 131:71-73.
8. Garrett I.R., Chen D., Gutierrez G., et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 2003, 111:1771-1782.
9. Giuliani N., Morandi F., Tagliaferri S., et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007, 110:334-338.
10. Mukherjee S., Raje N., Schoonmaker J.A., et al. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 2008, 118:491-504.
11. Qiang Y.W., Hu B., Chen Y., et al. Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood 2009, 113:4319-4330.
12. Oyajobi B.O., Garrett I.R., Gupta A., et al. Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br J Haematol 2007, 139:434-438.
13. Pennisi A., Li X., Ling W., Khan S., Zangari M., Yaccoby S. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol 2009, 84:6-14.
14. Heider U., Kaiser M., Muller C., et al. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol 2006, 77:233-238.
15. Shimazaki C., Uchida R., Nakano S., et al. High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation. Leukemia 2005, 19:1102-1103.
16. Zangari M., Yaccoby S., Cavallo F., Esseltine D., Tricot G. Response to bortezomib and activation of osteoblasts in multiple myeloma. Clin Lymphoma Myeloma 2006, 7:109-114.
17. Lund T., Soe K., Abildgaard N., et al. First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro. Eur J Haematol 2010, 85:290-299.
18. Zangari M., Aujay M., Zhan F., et al. Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. Eur J Haematol 2011, 86:484-487.
19. Silvestris F., Cafforio P., Calvani N., Dammacco F. Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. Br J Haematol 2004, 126:475-486.
20. Silvestris F., Cafforio P., Tucci M., Grinello D., Dammacco F. Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease. Br J Haematol 2003, 122:39-52.
21. Prockop D.J. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997, 276:71-74.
22. Barille S., Collette M., Bataille R., Amiot M. Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Blood 1995, 86:3151-3159.
23. Giuliani N., Colla S., Morandi F., et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005, 106:2472-2483.
24. Evans C.E., Ward C., Rathour L., Galasko C.B. Myeloma affects both the growth and function of human osteoblast-like cells. Clin Exp Metastasis 1992, 10:33-38.
25. Krishnan V., Bryant H.U., Macdougald O.A. Regulation of bone mass by Wnt signaling. J Clin Invest 2006, 116:1202-1209.
26. Ducy P., Zhang R., Geoffroy V., Ridall A.L., Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997, 89:747-754.
27. Qiang Y.W., Endo Y., Rubin J.S., Rudikoff S. Wnt signaling in B-cell neoplasia. Oncogene 2003, 22:1536-1545.
28. Qiang Y.W., Walsh K., Yao L., et al. Wnts induce migration and invasion of myeloma plasma cells. Blood 2005, 106:1786-1793.
29. Aberle H., Bauer A., Stappert J., Kispert A., Kemler R. beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997, 16:3797-3804.
30. Kisselev A.F., Goldberg A.L. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001, 8:739-758.
31. Day T.F., Guo X., Garrett-Beal L., Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 2005, 8:739-750.
32. Qiang Y.W., SRudikoff S. Wnt signaling pathways in multiple myeloma (chapter 2). Multiple myeloma: symptoms, diagnosis and treatment 2010, 51-75. Nova Science Publishers, New York. M. Georgiev, E. Bachev (Eds.).
33. Heider U., Kaiser M., Mieth M., et al. Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment. Eur J Haematol 2009, 82:31-38.
34. Kaiser M., Mieth M., Liebisch P., et al. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol 2008, 80:490-494.
35. Pinzone J.J., Hall B.M., Thudi N.K., et al. The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood 2009, 113:517-525.
36. Politou M.C., Heath D.J., Rahemtulla A., et al. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer 2006, 119:1728-1731.
37. Tian E., Zhan F., Walker R., et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003, 349:2483-2494.
38. Qiang Y.W., Barlogie B., Rudikoff S., Shaughnessy J.D. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone 2008, 42:669-680.
39. Qiang Y.W., Shaughnessy J.D., Yaccoby S. Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood 2008, 112:374-382.
40. Yaccoby S., Ling W., Zhan F., Walker R., Barlogie B., Shaughnessy J.D. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007, 109:2106-2111.
41. Edwards C.M., Edwards J.R., Lwin S.T., et al. Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 2008, 111:2833-2842.
42. Ng A.C., Khosla S., Charatcharoenwitthaya N., et al. Bone microstructural changes revealed by HRpQCT imaging and elevated DKK1 and MIP-1alpha levels in patients with monoclonal gammopathy of undetermined significance. Blood 2011, 118:6529-6534.
43. Oshima T., Abe M., Asano J., et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005, 106:3160-3165.
44. Qiang Y.W., Chen Y., Stephens O., et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 2008, 112:196-207.
45. Terpos E., Heath D.J., Rahemtulla A., et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 2006, 135:688-692.
46. Komori T. Runx2, a multifunctional transcription factor in skeletal development. J Cell Biochem 2002, 87:1-8.
47. Zhao M., Qiao M., Oyajobi B.O., Mundy G.R., Chen D. E3 ubiquitin ligase Smurf1 mediates core-binding factor alpha1/Runx2 degradation and plays a specific role in osteoblast differentiation. J Biol Chem 2003, 278:27939-27944.
48. Shui C., Spelsberg T.C., Riggs B.L., Khosla S. Changes in Runx2/Cbfa1 expression and activity during osteoblastic differentiation of human bone marrow stromal cells. J Bone Miner Res 2003, 18:213-221.
49. Giuliani N., Rizzoli V., Roodman G.D. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 2006, 108:3992-3996.
50. Sezer O., Heider U., Zavrski I., Kuhne C.A., Hofbauer L.C. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003, 101:2094-2098.
51. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
52. O'Brien C.A. Control of RANKL gene expression. Bone 2010, 46:911-919.
53. Terpos E., Szydlo R., Apperley J.F., et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003, 102:1064-1069.
54. Zavrski I., Krebbel H., Wildemann B., et al. Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. Biochem Biophys Res Commun 2005, 333:200-205.
55. Ang E., Pavlos N.J., Rea S.L., et al. Proteasome inhibitors impair RANKL-induced NF-kappaB activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and IkappaBalpha signaling cascades. J Cell Physiol 2009, 220:450-459.
56. von Metzler I., Krebbel H., Hecht M., et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 2007, 21:2025-2034.
57. Breitkreutz I., Raab M.S., Vallet S., et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008, 22:1925-1932.
58. Boissy P., Andersen T.L., Lund T., Kupisiewicz K., Plesner T., Delaisse J.M. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions. Leuk Res 2008, 32:1661-1668.
59. Terpos E., Kastritis E., Roussou M., et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 2008, 22:2247-2256.
60. Uy G.L., Trivedi R., Peles S., et al. Bortezomib inhibits osteoclast activity in patients with multiple myeloma. Clin Lymphoma Myeloma 2007, 7:587-589.
61. Glass D.A., Bialek P., Ahn J.D., et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005, 8:751-764.
62. Holmen S.L., Zylstra C.R., Mukherjee A., et al. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem 2005, 280:21162-21168.
63. Spencer G.J., Utting J.C., Etheridge S.L., Arnett T.R., Genever P.G. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci 2006, 119:1283-1296.
64. Willert J., Epping M., Pollack J.R., Brown P.O., Nusse R. A transcriptional response to Wnt protein in human embryonic carcinoma cells. BMC Dev Biol 2002, 2:8.
65. Qiang Y.W., Chen Y., Brown N., et al. Characterization of Wnt/beta-catenin signalling in osteoclasts in multiple myeloma. Br J Haematol 2010, 148:726-738.
66. Hongming H., Jian H. Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6. Leuk Res 2009, 33:115-122.
67. Meller R., Cameron J.A., Torrey D.J., et al. Rapid degradation of Bim by the ubiquitin-proteasome pathway mediates short-term ischemic tolerance in cultured neurons. J Biol Chem 2006, 281:7429-7436.
68. Akiyama T., Bouillet P., Miyazaki T., et al. Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3-only Bcl-2 family member Bim. EMBO J 2003, 22:6653-6664.
69. Roccaro A.M., Hideshima T., Raje N., et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006, 66:184-191.